Mississippi Department of Mental Health Selects CoCENTRIX for EHR and to Coordinate Care for Its Citizens Treated in State Behavioral Health and I/DD Programs

CoCENTRIX, a leading provider of coordinated care solutions to state Health and Human Services and community-based providers, is pleased to announce that the Mississippi Department of Mental Health (DMH) selected the CoCENTRIX Coordinated Care Platform (CoCENTRIXccp) as the solution to manage the Health Records and to coordinate care within and amongst its state behavioral health programs as well as its centers and programs dedicated to the care of individuals with intellectual and developmental disabilities (IDD).

As a result, the CoCENTRIXccp will be implemented in the following behavioral health programs: South Mississippi State Hospital (Purvis), East Mississippi State Hospital (Meridian), Specialized Treatment Facility (Gulfport), and Central Mississippi Residential Center (Newton). CoCENTRIX currently facilitates the delivery of mental health services for the Mississippi State Hospital in Whitfield and North Mississippi State Hospital in Tupelo.

Additionally, the following intellectual and developmental disability programs will utilize Mississippi’s coordinated care platform: Hudspeth Regional Center (Whitfield), Boswell Regional Center (Magee), South Mississippi Regional Center (Long Beach), Ellisville State School (Ellisville), Mississippi Adolescent Center (Brookhaven), and North Mississippi Regional Center (Oxford).

The CoCENTRIXccp provides the DMH with the ability to share data across programs; coordinate care and transition individuals into community-based programs; facilitate a central point of access for health records and care plans; standardize interfaces with ancillary systems; centralize back up, security and system access; and improve disaster recovery to ensure business continuity.

According to James Dunaway, Chief Information Officer, MS DMH, the CoCENTRIXccp was a “natural fit.”

The CoCENTRIXccp will provide the behavioral health and IDD programs with an integrated, ONC-ACB certified Electronic Health Record, Case Management, and mobile consumer applications designed specifically for the needs of each individual served. Additionally, the CoCENTRIXccp solution will allow the programs to share a common platform that is consistent with the CoCENTRIX system currently deployed at the Mississippi State Hospital and several other mental health programs in the State. These vital tools for coordinating care within and between programs also provide powerful reporting tools to meet the State reporting requirements as well as the Federal requirements for meaningful use of electronic health records.

“CoCENTRIXccp will allow us to centralize the data for our programs, eliminating duplication of data and eliminating the need for multiple local databases," said Dunaway. "This means that our programs will have centralized access to the system and the files will be preserved and accessible even in the event of a disaster in the region.”

Through the use of the CoCENTRIXccp, DMH will also be able to provide access to consumers and their families through the use of CARETILES, CoCENTRIX’s mobile “Connected Consumer” applications – allowing them to be active participants in their own care plans.

“CoCENTRIX is delighted to have been chosen to partner with the Mississippi Department of Mental Health,” stated Leigh Orlov, President of CoCENTRIX. “With the deployment of our Coordinated Care Platform, the State’s programs will now have the ability to provide the most comprehensive, collaborative, and personalized care possible to Mississippi’s most vulnerable citizens.”

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.